Daiichi Sankyo to boost ADC manufacturing; Eli Lilly looks to outer space; new FDA initiative for manufacturing tech
02 Nov 2023
ADC
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential updates on new builds, collaborations, recalls and more. This week, we look into Eli Lilly joining Redwire’s initiative to manufacture pharmaceuticals in space, as well as Exela Pharma’s recall of three injectables.
Daiichi Sankyo boosts ADC capacity
Daiichi Sankyo is absorbing two of its wholly-owned manufacturing companies, Daiichi Sankyo Propharma and Daiichi Sankyo Chemical Pharma, effective April 2025. Announced on Tuesday, the move expands Daiichi’s capacity to supply and manufacture antibody-drug conjugates, as well as develop new modalities.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.